Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use

被引：17
作者：
Zanotti, Laura [1 ]
Bottini, Alberto [1 ]
Rossi, Camillo [2 ]
Generali, Daniele [1 ]
Cappelletti, Maria Rosa [1 ]
机构：
[1] AO Ist Ospitalieri Cremona, I-26100 Cremona, Italy
[2] AO Ist Ospitalieri Cremona, Off Clin Trials, I-26100 Cremona, Italy
来源：
TUMOR BIOLOGY | 2014年 / 35卷 / 09期
关键词：
Adjuvant chemotherapy; Breast cancer; Genomic profile; Health economics; Personalized medicine; 21-GENE RECURRENCE SCORE; 70-GENE PROGNOSIS-SIGNATURE; INTERNATIONAL EXPERT CONSENSUS; RT-PCR ASSAY; ONCOTYPE DX; COST-EFFECTIVENESS; DECISION-MAKING; ADJUVANT CHEMOTHERAPY; DISTANT RECURRENCE; TREATMENT RECOMMENDATIONS;
D O I：
10.1007/s13277-014-2366-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Breast cancer is a complex disease with heterogeneous presentation and clinical course. The last decade has witnessed the development, commercialization, and increasing use of multigene assays, designed to support physicians and patients in clinical decision making in early-stage breast cancer. These include Oncotype DXA (R), MammaPrintA (R), and Prosigna (TM) assays. The assays differ in the technological platforms used for assessment of gene expression, in the number of genes and in the specific genes that are being tested, in the patient populations used for their development and validation, and in their clinical utility. This review focuses on these three commercialized assays, their development, validation, and clinical utility. The review also addresses ongoing prospective trials investigating these assays and health-economic considerations relating to their use.
引用
收藏
页码：8461 / 8470
页数：10
相关论文
共 84 条
  • [1] Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
  • [2] AGO) TGWGoGO, 2014, DIAGN TREATM PAT PRI
  • [3] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
    Albain, K.
    Anderson, S.
    Arriagada, R.
    Barlow, W.
    Bergh, J.
    Bliss, J.
    Buyse, M.
    Cameron, D.
    Carrasco, E.
    Clarke, M.
    Correa, C.
    Coates, A.
    Collins, R.
    Costantino, J.
    Cutter, D.
    Cuzick, J.
    Darby, S.
    Davidson, N.
    Davies, C.
    Davies, K.
    Delmestri, A.
    Di Leo, A.
    Dowsett, M.
    Elphinstone, P.
    Evans, V.
    Ewertz, M.
    Gelber, R.
    Gettins, L.
    Geyer, C.
    Goldhirsch, A.
    Godwin, J.
    Gray, R.
    Gregory, C.
    Hayes, D.
    Hill, C.
    Ingle, J.
    Jakesz, R.
    James, S.
    Kaufmann, M.
    Kerr, A.
    MacKinnon, E.
    McGale, P.
    McHugh, T.
    Norton, L.
    Ohashi, Y.
    Paik, S.
    Pan, H. C.
    Perez, E.
    Peto, R.
    Piccart, M.
    [J]. LANCET, 2012, 379 (9814) : 432 - 444
  • [4] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
    Albain, Kathy S.
    Barlow, William E.
    Shak, Steven
    Hortobagyi, Gabriel N.
    Livingston, Robert B.
    Yeh, I-Tien
    Ravdin, Peter
    Bugarini, Roberto
    Boehner, Frederick L.
    Davidson, Nancy E.
    Sledge, George W.
    Winer, Eric P.
    Hudis, Clifford
    Ingle, James N.
    Perez, Edith A.
    Pritchard, Kathleen I.
    Shepherd, Lois
    Gralow, Julie R.
    Yoshizawa, Carl
    Allred, D. Craig
    Osborne, C. Kent
    Hayes, Daniel F.
    [J]. LANCET ONCOLOGY, 2010, 11 (01) : 55 - 65
  • [5] Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER plus ) node-negative breast cancer
    Albanell, J.
    Gonzalez, A.
    Ruiz-Borrego, M.
    Alba, E.
    Garcia-Saenz, J. A.
    Corominas, J. M.
    Burgues, O.
    Furio, V.
    Rojo, A.
    Palacios, J.
    Bermejo, B.
    Martinez-Garcia, M.
    Limon, M. L.
    Munoz, A. S.
    Martin, M.
    Tusquets, I.
    Rojo, F.
    Colomer, R.
    Faull, I.
    Lluch, A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (03) : 625 - 631
  • [6] Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
    不详
    [J]. LANCET ONCOLOGY, 2007, 8 (12) : 1079 - 1087
  • [7] [Anonymous], 2013, PROS PROS PACK INS
  • [8] [Anonymous], SAN ANT BREAST CANC
  • [9] Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad, Juhi
    Jacobson, Allyson F.
    Estabrook, Alison
    Smith, Sharon Rosenbaum
    Boolbol, Susan K.
    Feldman, Sheldon M.
    Osborne, Michael P.
    Boachie-Adjei, Kwadwo
    Twardzik, Wendy
    Tartter, Paul I.
    [J]. AMERICAN JOURNAL OF SURGERY, 2008, 196 (04) : 527 - 529
  • [10] Bargallo JER, 2012, EUR SOC MED ONC 2012
123456789